POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients-Reference-Cited by-同舟云学术

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Published:2019-08-22 Issue:22 Volume:25 Page:6598-6605
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Baird Richard D.^ORCID,van Rossum Annelot G.J.,Oliveira Mafalda^ORCID,Beelen Karin,Gao Meiling,Schrier Mariette,Mandjes Ingrid A.M.,Garcia-Corbacho Javier,Vallier Anne-Laure,Dougall Greig^ORCID,van Werkhoven Erik^ORCID,Linossi Constanza^ORCID,Kumar Sanjeev^ORCID,van Tinteren Harm,Callari Maurizio,Beddowes Emma^ORCID,Perez-Garcia José-Manuel,Rosing Hilde,Platte Else,Nederlof Petra^ORCID,Schot Margaret,de Vries Schultink Aurelia,Bernards René,Saura Cristina^ORCID,Gallagher William,Cortès Javier^ORCID,Caldas Carlos,Linn Sabine C.

Funder

Genentech, and led by the Netherlands Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy modulation in cancer therapy: Challenges coexist with opportunities;European Journal of Medicinal Chemistry;2024-10

2. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

3. Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development;Interdisciplinary Cancer Research;2024

4. The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management;Cancers;2023-11-17

5. Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements;Cancers;2023-02-23